ARB-085

N/A

Report date: 2026/05/08 20:02:52

NME

Base Information

Drug NameARB-085

Drug Alias NameARB-085

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionEGFR exon 20 insertion mutations inhibitorsEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2EGFR exon 20 insertion mutations

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPolymed Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesPolymed Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A